Education
About Us
Working with TipRanks
Follow Us
Insulet (PODD)
NASDAQ:PODD
PODD Stock Chart & Stats
$333.47
$3.66(1.38%)
At close: 4:00 PM EST
$333.47
$3.66(1.38%)
Day’s Range― - ―
52-Week Range$230.05 - $353.50
Previous CloseN/A
Volume86.50K
Average Volume (3M)527.36K
Market Cap
$23.40B
Enterprise Value$22.09B
Total Cash (Recent Filing)$757.40M
Total Debt (Recent Filing)$1.03B
Price to Earnings (P/E)95.2
Beta0.76
Next Earnings
Feb 19, 2026EPS Estimate
1.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.24
Shares Outstanding70,346,900
10 Day Avg. Volume685,352
30 Day Avg. Volume527,356
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)15.10
Price to Sales (P/S)8.83
P/FCF Ratio59.90
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue8.76
Enterprise Value/Gross Profit12.26
Enterprise Value/Ebitda49.87
Forecast
1Y Price Target
$377.06Price Target Upside13.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial Performance And GuidanceQ3 revenue and EPS of $706M and $1.24 sailed past Street estimates of $678M and $1.14.
Market Share And GrowthPODD is currently the market leader in the US with 37% patient share and capturing 60-65% of new pumpers.
Product Launch And ExpansionPODD is planning to launch O5 in new regions outside of the U.S. in 2026 upon regulatory approval.
Bears Say
Expense ManagementThe lone metric that did not beat the Street's projection was attributable to higher-than-anticipated SG&A expenses, at $315.2M vs the $288.4M forecast.
Future Earnings OutlookThe EPS estimate for 2026 has been adjusted downward.
Market Penetration ChallengesOverall AID penetration remains relatively low, with pump penetration at ~40% for U.S. Type 1 diabetes and only ~5% for Type 2 insulin-intensive patients in the U.S.
Insulet News
PODD FAQ
What was Insulet’s price range in the past 12 months?
Insulet lowest stock price was $230.05 and its highest was $353.50 in the past 12 months.
What is Insulet’s market cap?
Insulet’s market cap is $23.40B.
When is Insulet’s upcoming earnings report date?
Insulet’s upcoming earnings report date is Feb 19, 2026 which is in 91 days.
How were Insulet’s earnings last quarter?
Insulet released its earnings results on Nov 06, 2025. The company reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.1.
Is Insulet overvalued?
According to Wall Street analysts Insulet’s price is currently Undervalued.
Does Insulet pay dividends?
Insulet does not currently pay dividends.
What is Insulet’s EPS estimate?
Insulet’s EPS estimate is 1.45.
How many shares outstanding does Insulet have?
Insulet has 70,346,900 shares outstanding.
What happened to Insulet’s price movement after its last earnings report?
Insulet reported an EPS of $1.24 in its last earnings report, beating expectations of $1.14. Following the earnings report the stock price went up 2.85%.
Which hedge fund is a major shareholder of Insulet?
Currently, no hedge funds are holding shares in PODD
Insulet Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$377.06 (13.07% Upside)
$377.06 (13.07% Upside)
Blogger Sentiment
Bullish
PODD Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 32.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $516.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.6%
Last 30 Days ▲ 4.8%
Last 30 Days ▲ 4.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.92%
12-Months-Change
Fundamentals
Return on Equity
19.68%
Trailing 12-Months
Asset Growth
0.13%
Trailing 12-Months
Company Description
Insulet
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
PODD Company Deck
PODD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance with record revenue growth, particularly in international markets and the U.S. Type 2 segment. Operating margins have improved, and the company has successfully managed its debt. However, there are increased R&D expenses and higher interest expenses due to debt restructuring.View all PODD earnings summariesPODD Revenue Breakdown
72.86% U.S. Omnipod
25.27% International Omnipod
1.88% Drug Delivery
PODD Stock 12 Month Forecast
Average Price Target
$377.06
▲(13.07% Upside)
Technical Analysis
Ownership Overview
0.39% Insiders
40.10% Mutual Funds
10.85% Other Institutional Investors
22.38% Public Companies and
Individual Investors